利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.049 秒)

    Blood group antigen panel
    7.
    发明授权
    Blood group antigen panel 失效
    血型抗原组

    公开(公告)号：US5168043A

    公开(公告)日：1992-12-01

    申请号：US330591

    申请日：1989-03-28

    申请人： Carlos Cordon-Cardo ,  Kenneth O. Lloyd ,  Connie L. Finstad ,  Lloyd J. Old ,  Mryon R. Melamed ,  Joel Sheinfeld

    发明人： Carlos Cordon-Cardo ,  Kenneth O. Lloyd ,  Connie L. Finstad ,  Lloyd J. Old ,  Mryon R. Melamed ,  Joel Sheinfeld

    IPC分类号： C07K16/30 ,  C07K16/34

    CPC分类号： C07K16/30 ,  C07K16/34 ,  Y10S435/96 ,  Y10S436/811 ,  Y10S436/813

    摘要： The subject invention describes a method of determining the secretor status of an individual which comprises obtaining a sample of a biological fluid from the individual and determining whether the sample includes the Lewis.sup.a or Lewis.sup.b antigens, the presence of the Lewis.sup.a antigen in the sample indicating that the individual is a nonsecretor, the presence of the Lewis.sup.b antigen in the sample indicating that the individual is a secretor, and the presence of neither antigen indicating the secretor status of the individual is inconclusive. The invention also provides a method of further determining the secretor status of an individual of having an inconclusive secretor status which comprises determining whether the biological fluid sample from the individual includes A, B or precursor type 1 chain antigens, the presence of any such antigens in the sample indicating that the individual is a secretor, the lack of any such antigens in the sample indicating that the individual is a nonsecretor. The invention provides a method of determining whether a human female subject is susceptible to urogenital infection which comprises determining whether the subject is a secretor according to the hereinabove-described methods, a secretor being susceptible to such an infection. The present application also provides a method of disstinguishing urothelial carcinoma from normal tissue, and identifying human germ cell tumor as seminoma or nonseminoma. Finally, the invention provides a panel comprising some or all of the monoclonal antibodies H 29-36 (ATCC No. HB 8248), S8 (ATCC No. HB 9036), T 174 (ATCC No. HB 8242), T 218 (ATCC No. HB 8249), P 12 (ATCC No. HB 8551), F 3 (ATCC No. HB 8217), and K 21 (ATCC No. HB 8549).

    摘要翻译： 本发明描述了一种确定个体的分泌状态的方法，其包括从个体获得生物流体的样品，并确定样品是否包含Lewisa或Lewisb抗原，样本中Lewisa抗原的存在表明 个体是不分泌者，样本中Lewisb抗原的存在表明个体是分泌体，并且不存在表示个体分泌体状态的抗原是不确定的。 本发明还提供了一种进一步确定具有不确定分泌状态的个体的分泌状态的方法，其包括确定来自个体的生物流体样品是否包含A，B或前体1型链抗原，任何此类抗原存在于 样本表明个体是分泌体，样本中缺少任何这样的抗原，表明个体是非分泌者。 本发明提供了一种确定人类雌性受试者是否易于感染泌尿生殖器感染的方法，其包括根据上述方法确定受试者是否是分泌器，分泌器对这种感染敏感。 本申请还提供了一种从正常组织中分离尿路上皮癌的方法，并将人类生殖细胞肿瘤鉴定为精原细胞瘤或非神经瘤。 最后，本发明提供了包含部分或全部单克隆抗体H29-36（ATCC No.BB8248），S8（ATCC No.HB9036），T174（ATCC No.BB8242），T1818（ATCC No.BB8249），P12（ATCC No.HB8551），F3（ATCC No.HB8217）和K21（ATCC No.HB8549）。

    Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
    9.
    发明申请
    Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition 有权
    用于治疗，诊断和预测医疗状况发生的系统和方法

    公开(公告)号：US20100184093A1

    公开(公告)日：2010-07-22

    申请号：US12584048

    申请日：2009-08-28

    申请人： Michael Donovan ,  Faisal Khan ,  Jason Alter ,  Gerardo Fernandez ,  Ricardo Mesa-Tejada ,  Douglas Powell ,  Valentina Bayer Zubek ,  Stefan Hamann ,  Carlos Cordon-Cardo ,  Jose Costa

    发明人： Michael Donovan ,  Faisal Khan ,  Jason Alter ,  Gerardo Fernandez ,  Ricardo Mesa-Tejada ,  Douglas Powell ,  Valentina Bayer Zubek ,  Stefan Hamann ,  Carlos Cordon-Cardo ,  Jose Costa

    IPC分类号： G01N33/53 ,  C12M1/34

    CPC分类号： G06F19/3437 ,  G06F19/00 ,  G16H50/20 ,  G16H50/50 ,  G16H50/70

    摘要： Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts whether a patient is likely to have a favorable pathological stage of prostate cancer, where the model is based on features including one or more (e.g., all) of preoperative PSA, Gleason Score, a measurement of expression of androgen receptor (AR) in epithelial and stromal nuclei and/or a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of a ratio of area of epithelial nuclei outside gland units to area of epithelial nuclei within gland units, and a morphometric measurement of area of epithelial nuclei distributed away from gland units. In some embodiments, quantitative measurements of protein expression in cell lines are utilized to objectively assess assay (e.g., multiplex immunofluorescence (IF)) performance and/or to normalize features for use within a predictive model.

    摘要翻译： 临床信息，分子信息和/或计算机生成的形态学信息用于预测医疗状况发生的预测模型中。 在一个实施方案中，模型预测患者是否可能具有前列腺癌的良好病理分期，其中模型基于包括术前PSA（Gleason Score），Gleason评分（Gleason Score）的一个或多个（例如全部） 雄激素受体（AR）在上皮和基质细胞核中的表达和/或Ki67阳性上皮细胞核的表达测量，腺体单位上皮细胞核的面积与腺体单位内上皮细胞核的比例的形态测量，以及形态学 上皮细胞核的分布远离腺体单位的面积测量。 在一些实施方案中，使用细胞系中的蛋白质表达的定量测量来客观地评估测定（例如，多重免疫荧光（IF））性能和/或归一化在预测模型中使用的特征。